Mankind Pharma PAT grew by 29% in Q2FY25
Mankind Pharma, India’s 4th largest pharmaceutical co, announced its financial results for the second quarter and six months ended 30 Sep
top of page
Oct 244 min read
Mankind Pharma completes landmark acquisition of BSV; Expands high entry barrier portfolio; Leadership in Women’s Health (#1 in Gynae IPM)
Mankind Pharma Limited has completed the transaction to acquire 100% stake in BSV for INR 13,768 Crores
Jul 265 min read
Mankind Pharma to acquire 100% stake in BSV; expands high entry barrier portfolio; Leadership in women’s health (#1 in Gynae IPM)
Mankind Pharma to acquire a 100% stake in Bharat Serums and Vaccines Limited (BSV) from Advent International (“Advent”) for INR 13,630 Cr
Jul 162 min read
Mankind Pharma signs Non-Exclusive Patent License Agreement with Takeda to commercialise Vonoprazan in India
The agreement with Takeda allows Mankind Pharma to launch the novel drug for treating Gastroesophageal Reflux Disease under its trademark
Feb 132 min read
Mankind Pharma combats leprosy: Announces strategic tie-up with Lepra Society to establish CDCCs, to screen 80,000 individuals
Under their CSR arm, the company is committed to making a meaningful impact in regions affected by leprosy.
bottom of page